Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym® extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

Delsym®, indicated for the temporary treatment of cough due to minor throat and bronchial irritation, has estimated annual sales of $100 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "We are excited to partner with Tris Pharma and bring this first ever store brand extended release liquid cough/cold product to our retail and store brand customers' portfolios in time for the season. This launch continues to demonstrate our commitment to making quality healthcare more affordable for consumers."

Ketan Mehta, Tris' CEO added, "When we developed our proprietary technology to deliver drugs in taste-neutral, extended release dosage forms such as liquids and ODT/chewable tablets, we were focused on improving the profile of new drugs. However, Delsym® presented a unique opportunity where we were able to leverage our technology to bring a long overdue lower cost alternative to consumers and I am delighted we were able to partner with Perrigo to do so."

SOURCE Perrigo Company